Cleveland Clinic’s Orthopaedic & Rheumatologic Institute is studying genetic polymorphisms with the aim of improving the understanding of why some individuals do not respond to TNFα blockers. The ultimate goal is to find a new therapeutic approach for those with PsA.
Using Patient-Reported Outcomes to Distinguish Between Low Disease Activity and Remission in Psoriatic Arthritis
Patient-reported outcomes can offer insights into the impact of psoriatic arthritis that aren’t readily obtained by standard composite instruments, laboratory data and clinical examinations.
Intravenous Golimumab for Psoriatic Arthritis: GO-VIBRANT at 1 Year
Intravenous golimumab is both safe and effective over a one-year treatment period for patients with psoriatic arthritis. Rheumatologist Elaine Husnie, MD, MPH, discusses the findings.
Joint ACR/NPF Psoriatic Arthritis Treatment Guidelines Emphasize Treat-to-Target Approach
Most of the guidelines are conditional but represent the best of evidence-based treatments for psoriatic arthritis.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Targeting Biomarkers of Nitric Oxide and Endothelial Dysfunction in RA and PsA
Translational work combining human plasma studies and previous mouse model data will enable identification of new, precise biomarkers and potential treatment pathways that may help pinpoint and treat RA and PsA patients at increased risk of CV disease.
Search Is On for Genomic Clues in Psoriatic Arthritis
Here’s why psoriatic arthritis is among the first clinical areas Cleveland Clinic’s collaborative Center for Clinical Genomics has chosen to focus on.
New Research Lab Brings an Interdisciplinary Approach to Psoriatic Diseases
The Husni research lab combines clinical savvy with biochemical and molecular biology expertise to home in on the molecular basis of immune-mediated diseases. An early focus: selective TNF-α receptor inhibition.
In Psoriatic Diseases, HDL-Associated Antioxidant Enzymes Show Promise as a Cardiac Risk Tool
Here’s early evidence that activity levels of HDL-associated antioxidant enzymes might prove to be a much-needed predictor of cardiovascular risk in systemic rheumatic diseases.
Guidance at Last on Managing Comorbidities of Psoriatic Arthritis
Updated treatment guidelines from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis include a section on managing comorbidities and extra-articular manifestations in psoriatic arthritis patients.
Assessing Cardiovascular Disease Risk in Psoriatic Arthritis Patients
Carotid ultrasound is a pragmatic way to assess cardiac risk in patients with psoriatic arthritis and identify those who would benefit from early interventions